Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0T6FH
|
||||
| Former ID |
DIB018370
|
||||
| Drug Name |
[3H]OT (human, mouse, rat)
|
||||
| Synonyms |
[3H]oxytocin
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [539378] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C43H66N12O12S2
|
||||
| InChI |
InChI=1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1
|
||||
| InChIKey |
XNOPRXBHLZRZKH-DSZYJQQASA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
4008, 7847157, 7980241, 10298288, 12014072, 14816702, 14865724, 24897975, 24897994, 36883548, 47797109, 50112429, 50139454, 53837750, 57402962, 57654742, 78163598, 93815090, 103530389, 104084247, 104620165, 127284169, 127284170, 127284171, 127284172, 127284173, 134338401, 134971638, 135651848, 135652589, 136104920, 137002863, 137212930, 152134076, 162172940, 162224738, 164831947, 179293013, 187072147, 223398144, 224051785, 226416223, 241088619, 252156176, 252218811
|
||||
| Target and Pathway | |||||
| Target(s) | Oxytocin receptor | Target Info | Agonist | [533541] | |
| Vasopressin V1a receptor | Target Info | Agonist | [534487] | ||
| Vasopressin V1b receptor | Target Info | Agonist | [534481] | ||
| Vasopressin V2 receptor | Target Info | Agonist | [543798] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Oxytocin signaling pathwayhsa04020:Calcium signaling pathway | |||||
| Vascular smooth muscle contractionhsa04020:Calcium signaling pathway | |||||
| Vascular smooth muscle contractionhsa04080:Neuroactive ligand-receptor interaction | |||||
| Vasopressin-regulated water reabsorption | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| PANTHER Pathway | Oxytocin receptor mediated signaling pathway | ||||
| Pathway Interaction Database | Arf6 trafficking events | ||||
| PathWhiz Pathway | Vasopressin Regulation of Water Homeostasis | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Myometrial Relaxation and Contraction Pathways | |||||
| Oxytocin signaling | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| Regulation of Water Balance by Renal Aquaporins | |||||
| GPCR downstream signaling | |||||
| References | |||||
| Ref 533541 | Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor. Science. 1982 Mar 12;215(4538):1396-8. | ||||
| Ref 534481 | The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22. | ||||
| Ref 534487 | Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44. | ||||
| Ref 543798 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.